Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Accured Expenses (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Change in Accured Expenses for 14 consecutive years, with $865000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 32.06% year-over-year to $865000.0, compared with a TTM value of -$9.0 million through Dec 2025, down 443.47%, and an annual FY2025 reading of -$9.0 million, down 443.47% over the prior year.
  • Change in Accured Expenses was $865000.0 for Q4 2025 at Fate Therapeutics, up from -$550000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $10.3 million in Q3 2022 and bottomed at -$20.4 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$973450.0, with a median of $402000.0 recorded in 2024.
  • Peak annual rise in Change in Accured Expenses hit 309.41% in 2021, while the deepest fall reached 1068.28% in 2021.
  • Year by year, Change in Accured Expenses stood at -$10.4 million in 2021, then surged by 132.63% to $3.4 million in 2022, then plummeted by 155.89% to -$1.9 million in 2023, then skyrocketed by 134.6% to $655000.0 in 2024, then soared by 32.06% to $865000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for FATE at $865000.0 in Q4 2025, -$550000.0 in Q3 2025, and $484000.0 in Q2 2025.